<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.1 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html lang="en" xml:lang="en" xmlns="http://www.w3.org/1999/xhtml">
<head>
	<meta content="text/html; charset=utf-8" http-equiv="Content-Type" />
	<meta content="Denovo Biomarkers: A next generation biomarker partner to personalize your drug" name="description" />
	<meta content="your,keywords,goes,here" name="Clinical Biomarkers" />
	<meta content="Denovo Biomarkers" name="Webmaster" />
	<link href="denovo.css" media="all" rel="stylesheet" title="Denovo Biomarkers" type="text/css" />
	<title>Denovo Biopharma Homepage</title>
	<style type="text/css"><!--
.style1 {font-size: x-large}
.style4 {color: #00FF33}
.style5 {color: #0066FF}
.style6 {
	color: #999999;
	font-style: italic;
	font-weight: bold;
	font-size: medium;
}
-->
	</style>
</head>
<body>
<div id="width960">
<div class="row" id="header">
<div class="col c12">
<p class="style1"><a href="index.html"><img alt="Denovo Biomarkers" src="images/header.jpg" /></a></p>
</div>
</div>

<div class="row">
<div class="col c3" id="sidebar">
<ul class="menu">
	<li><a href="index.html">Homepage</a></li>
	<li><a class="box" href="index3.html">Management</a></li>
	<li><a href="index7.html">Advisors</a></li>
	<li><a href="index4.html">Technology</a></li>
	<li><a href="index8.html">Pipeline</a></li>
	<li><a href="index6.html">News</a></li>
	<li><a href="index5.html">Contact us</a></li>
	<li><a href="/Chinese/index.html">中文</a></li>
</ul>
</div>

<div class="col c9" id="content">
<div class="row">
<div class="col c9">
<h2 align="left"><span class="style4">Denovo</span> <span class="style5">Biopharma</span></h2>

<p align="justify"><strong><font size="4">Wen Luo, Ph.D. - Chief Executive Officer, Chief Scientific Officer</font></strong></p>

<p><img style="padding: 0 15px; float: left;" src="images/Wen_Luo_Pic.jpg" alt="Wen_Luo_Pic.jpg" width="200", height="255"/></p>
<p style="margin-top: 20px;"></p>
<p align="justify">Dr. Wen Luo has over 20 years of experience in biomedical research and industry including more than 15 years of experience in applying genomic technology in drug discovery and development. Prior to founding Denovo Biopharma, Dr. Luo managed the genomic group and provided bioinformatic support to a broad range of research projects across a number of therapeutic areas including oncology, hematology, inflammation and metabolic diseases at Ligand Pharmaceuticals. He was also responsible for developing clinical biomarkers for drugs in various stages of clinical trials. Before joining Ligand, he was a senior bioinformatician at Incyte Genomics, where he managed one of the largest proteomic databases, LifePro. He was also involved in discovering novel human genes and splice variants, and was the co-inventor of patents covering hundreds of novel genes derived from these findings. Prior to Incyte Genomics, he was a research scientist at Sugen, which had been acquired by Pharmacia, where he worked on drug target identification and validation for a number of novel kinases discovered at Sugen. Dr. Luo was a Howard Hughes Medical Institute post-doc fellow at the University of California, San Francisco, and received his Ph.D. in Molecular Biology and Biochemistry from Indiana University School of Medicine. Dr. Luo received pre-med training at Peking University and medical training at Peking Union Medical College.</p>


<p align="justify"><strong><font size="3">Ronald L. Shazer, M.D. - Chief Medical Officer</font></strong></p>
<p><img style="padding: 0 15px; float: left;" src="images/Ronald_Shazer_Pic.jpg" alt="Ronald_Shazer_Pic.jpg" width="200", height="255"/></p>
<p style="margin-top: 20px;"></p>
<p align="justify">Dr. Shazer has more than 10 years of clinical research experience, initially as an investigator on multiple clinical trials and subsequently leading the development of therapeutics in the biopharmaceutical industry. Dr. Shazer served as Senior Vice President and Chief Medical Officer at Inspyr Therapeutics until December 2017. Previously he served as Chief Medical Officer at Tracon Pharmaceuticals. Both Inspyr Therapeutics and Tracon Pharmaceuticals are clinical stage biopharmaceutical companies developing targeted therapies for cancer. Prior to Tracon Pharmaceuticals, he was Senior Director, Clinical Lead Oncology at Pfizer, where he led the clinical development of multiple oncology compounds including antibody drug conjugates, dual targeting T cell engaging antibodies and immuno-oncology small molecules. Prior to Pfizer, he was Director, Clinical Research Oncology at Bristol-Myers Squibb and served as the study lead on the registration trial for elotuzumab (EMPLICITI™), a therapy for multiple myeloma that subsequently received FDA approval. He also served as Head of Clinical Development at Arena Pharmaceuticals during which time the company filed a new drug application (NDA) for lorcaserin (Belviq®). Dr. Shazer previously held academic positions in the Department of Medicine at the University of California, San Diego, University of California, Los Angeles School of Medicine and Cedars-Sinai Medical Center. He received his B.A. in economics from the University of California, San Diego, M.D. from New York Medical College, and MBA. from the Anderson School of Management, University of California, Los Angeles. He completed his residency in internal medicine at Cedars-Sinai Medical Center in 2004.</p>


<p align="justify"><strong><font size="3">Robert Little - Chief Business Officer</font></strong></p>
<p><img style="padding: 0 15px; float: left;" src="images/Robert_Little_Pic.jpg" alt="Robert_Little_Pic.jpg" width="200", height="255"/></p>
<p style="margin-top: 20px;"></p>
<p align="justify">Robert Little has over 30 years of commercial experience in the pharmaceutical, biotechnology and medical device industries, with leadership roles in in country management, global product launches, and business development and licensing. From 2006-2010, Mr. Little was Vice President and Chief Commercial Officer at Halozyme Therapeutics, where he implemented a high performing commercial operations function including business development, marketing, new product planning and alliance management. From 2003 -2006, Mr. Little was Senior Vice President at Neurocrine Biosciences, where he implemented a 200-person commercial organization with integrated sales, marketing and new product planning capabilities to initially co-promote Zoloft™ with Pfizer then subsequently launch Indiplon for sleep disorders. Prior to 2003, Mr. Little was Group Vice President of Global Prescription business at Pharmacia after spending nearly 20 years at Pharmacia and Pharmacia & Upjohn. Mr. Little has had business experience working in four different countries, and has deep experience in many therapeutic areas, particularly in oncology, endocrinology, neuroscience, and ophthalmology. His additional experience includes creating a global reimbursement and health outcomes function for Pharmacia, as well as building from the ground up commercial organizations for three early stage biotech companies. He has led successful licensing activities and, over a 10-year period, created licensing agreements with an aggregate value of over $1 billion, including upfront payments and milestones. Mr. Little earned a B.A. in Economics and Finance from West London College.</p>


<p align="justify"><strong><font size="3">Xiangming Fang, M.D., Ph.D. - Chief Operating Officer</font></strong></p>
<p><img style="padding: 0 15px; float: left;" src="images/XiangMing_Fang_Pic.jpg" alt="XiangMing_Fang_Pic.jpg" width="200", height="255"/></p>
<p style="margin-top: 20px;"></p>
<p align="justify">Dr. Fang has 20+ years of experience in biomedical research and product development. She has a strong scientific background with integrated knowledge in medicine, molecular and cell biology, immunology, genomics and proteomics. She was also involved in several startup companies where she gained experience in team building and operations. Previously as the Senior Vice President and Chief Scientific Officer at GenWay Biotech, she was responsible for new technology and product development and production, as well as customer support and partnership coordination. Prior to GenWay, Dr. Fang served at GenStar Therapeutics, initially as the Director of the Cancer Program and the Director of Preclinical Studies, then as Vice President, Hemophilia and Vector Development. Dr. Fang's earlier experience includes gene therapy product development for hemophilia at Baxter Healthcare and GeneMedicine Inc. Dr. Fang obtained her M.D. from Zhejiang University Medical School and Ph.D. in Molecular Biology from the University of Alabama. She completed her postdoctoral studies at the University of Texas, MD Anderson Cancer Center. Dr. Fang was the President (2009-2010) of Sino-American Biomedical and Pharmaceutical Professionals Association (SABPA), San Diego chapter, and Chair of Board of Directors (2013-2015).</p>


<p align="justify"><strong><font size="3">Michael Haller, Ph.D. - Chief Financial Officer</font></strong></p>
<p><img style="padding: 0 15px; float: left;" src="images/Michael_Haller_Pic.jpg" alt="Michael_Haller_Pic.jpg" width="200", height="255"/></p>
<p style="margin-top: 20px;"></p>
<p align="justify">Dr. Haller has broad experience in finance, business development and alliance management, drug development, and corporate and product strategy, currently leading the Finance and Accounting team at Denovo Biopharma. Prior to Denovo, he was Chief Business Officer, responsible for business development, finance, and accounting, at Peloton Therapeutics. As Vice President of Business Development and Alliance Management at Ligand Pharmaceuticals, Dr. Haller was responsible for out-licensing activities and managing Ligand’s numerous alliances.  Before Ligand, he was Senior Vice President of Strategic Partnerships at Anaphore, now Bird Rock Bio. He joined Anaphore from Halozyme Therapeutics, where he served as Head of Halozyme’s drug delivery franchise, Enhanze Technology, and Vice President of Alliance Management.  There he directed key alliances with Roche and Baxter Healthcare from deal signing through registration submissions, which resulted in several approved drugs, including Herceptin SC®, Mabthera SC®, and HyQvia®.  Prior to Halozyme, Dr. Haller was a McKinsey & Company management consultant focusing on complex health care issues for a number of Fortune 500 companies. Dr. Haller has published several peer-reviewed articles, presented at numerous scientific conferences, and is co-inventor on multiple patents. Dr. Haller earned his Ph.D. in Biomedical Engineering from The Johns Hopkins University School of Medicine, his MS in Chemical Engineering from Cornell University and his B.S. in Biomedical Engineering from The Johns Hopkins University.</p>


<p align="justify"><strong><font size="3">Xiao-Xiong Lu, Ph.D. - Chief Technical Officer</font></strong></p>
<p><img style="padding: 0 15px; float: left;" src="images/XiaoXiong_Lu_Pic.jpg" alt="XiaoXiong_Lu_Pic.jpg" width="200", height="255"/></p>
<p style="margin-top: 20px;"></p>
<p align="justify">Dr. Xiao-Xiong Lu has over 30 years of experience in the U.S. biotech and pharmaceutical industries including extensive experience in pharmaceutical CMC development, manufacturing and supply chain. He has also consulted for a number of biotech and pharmaceutical companies worldwide in the areas of CMC and business development. In February 2018, Dr. Lu joined Denovo Biopharma as Chief Technical Officer responsible for all aspects of pharmaceutical CMC development, manufacturing and supply chain. Prior to joining Denovo, he served as Vice President of Technical Operations at Balance Therapeutics with responsibility for pharmaceutical CMC development, manufacturing and supply chain. From 2003 to 2015, he was with Arena Pharmaceuticals, most recently as Associate VP of CMC Technical Operations as well as Managing Director for Greater China. At Arena, Dr. Lu led or made significant contributions to the CMC activities and functions for BELVIQ® (lorcaserin) for obesity, temanogrel for thrombosis, nelotanserin for sleep disorders, ralinepag for PAH, etrasimod for autoimmune diseases, and APD371 for pain. From 1990 to 2003, he worked at Monsanto Company and its spin-off Solutia Inc. with increasing responsibilities in R&D and manufacturing. He received his Ph.D. from University of Birmingham in the UK and BSc from University of Petroleum in China, in Chemical Engineering.</p>



<p align="justify">&nbsp;</p>

<p align="justify"></p>

<p align="justify"></p>
</div>
</div>

<div class="row">
<div class="col c3"></div>
</div>
</div>

<div class="row" id="footer">Denovo Biopharma Homepage &nbsp; &nbsp; &nbsp;&copy; 2018 Denovo Biopharma</div>
</div>
</div>
</body>
</html>
